Literature DB >> 14675569

Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease.

Yinong Young-Xu1, Samer Jabbour, Robert Goldberg, Charles M Blatt, Thomas Graboys, Brian Bilchik, Shmuel Ravid.   

Abstract

Atrial fibrillation (AF) is prevalent in the elderly, in patients with hypertension, and in patients with coronary artery disease (CAD). We hypothesized that statin therapy might be effective in preventing AF in patients with CAD and examined this hypothesis in a sample of patients with chronic stable CAD without AF, followed prospectively at a large outpatient cardiology practice. The association between statin use and the risk of developing AF was examined univariately and then with adjustment for potential confounding factors. Four hundred forty-nine men and women between the ages of 40 and 87 years were followed for an average of 5 years. Fifty-two patients (12%) developed AF during follow-up. Statin therapy was used by 59% of the patients during the study period and was associated with a significantly reduced risk of developing AF (crude odds ratio, 0.48, 95% confidence interval 0.28 to 0.83). This association remained significant after adjustment for potential confounders, including age, hypertension, left ventricular systolic function, occurrence of heart failure or acute ischemic events, and baseline cholesterol and changes in cholesterol levels (adjusted odds ratio 0.37, 95% confidence interval 0.18 to 0.76). Use of statins in patients with chronic stable CAD appears to be protective against AF. The underlying mechanism for this effect is unknown but appears to be independent of the reduction in serum cholesterol levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14675569     DOI: 10.1016/j.amjcard.2003.08.040

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  49 in total

1.  Biochemical predictors of cardiac rhythm at 1 year follow-up in patients with non-valvular atrial fibrillation.

Authors:  Mónica Acevedo; Ramón Corbalán; Sandra Braun; Jaime Pereira; Ilse González; Carlos Navarrete
Journal:  J Thromb Thrombolysis       Date:  2012-02-03       Impact factor: 2.300

2.  Left atrial epicardial adiposity and atrial fibrillation.

Authors:  Omar Batal; Paul Schoenhagen; Mingyuan Shao; Ala Eddin Ayyad; David R Van Wagoner; Sandra S Halliburton; Patrick J Tchou; Mina K Chung
Journal:  Circ Arrhythm Electrophysiol       Date:  2010-05-26

Review 3.  Atrial fibrillation: basic mechanisms, remodeling and triggers.

Authors:  Akiko Shiroshita-Takeshita; Bianca J J M Brundel; Stanley Nattel
Journal:  J Interv Card Electrophysiol       Date:  2005-09       Impact factor: 1.900

Review 4.  [Current strategies in the treatment of atrial fibrillation].

Authors:  Imke Drewitz; Thomas Rostock; Boris Hoffmann; Daniel Steven; Helge Servatius; Thomas Meinertz; Stephan Willems
Journal:  Med Klin (Munich)       Date:  2008-11-15

5.  Is there a link between gastroesophageal reflux disease and atrial fibrillation?

Authors:  Jeffrey S Kunz; Brian Hemann; J Edwin Atwood; Jeffrey Jackson; Timothy Wu; Carolyn Hamm
Journal:  Clin Cardiol       Date:  2009-10       Impact factor: 2.882

6.  Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction.

Authors:  Ibrahim R Hanna; Brent Heeke; Heather Bush; Lynne Brosius; Diane King-Hageman; Samuel C Dudley; John F Beshai; Jonathan J Langberg
Journal:  Heart Rhythm       Date:  2006-05-09       Impact factor: 6.343

7.  Pravastatin treatment before coronary artery bypass grafting for reduction of postoperative atrial fibrillation.

Authors:  Kiyoshi Tamura; Hirokuni Arai; Fusahiko Ito; Takeshi Someya; Tomohiro Ushiyama; Naoto Miyagi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-03-11

Review 8.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Eur J Prev Cardiol       Date:  2016-11-04       Impact factor: 7.804

9.  Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial.

Authors:  C N Pellegrini; E Vittinghoff; F Lin; S B Hulley; G M Marcus
Journal:  Heart       Date:  2009-01-28       Impact factor: 5.994

Review 10.  Pleiotropic effects of statins in atrial fibrillation patients: the evidence.

Authors:  Hadi Ar Hadi; Wael Al Mahmeed; Jassim Al Suwaidi; Samer Ellahham
Journal:  Vasc Health Risk Manag       Date:  2009-06-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.